Pacira BioSciences (PCRX) Total Debt Growth (1y) (2011 - 2026)
Pacira BioSciences (PCRX) Total Debt Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | -3.69% |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 37.49% |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -2.48% |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 4.38% |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | -6.91% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 41.53% |
| 10 | Pacira BioSciences | 970.37 Mn | 719.34 Mn | 148.24 Mn | -53.62% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -53.62% |
| Mar 31, 2026 | 21.11% |
| Dec 31, 2025 | -52.71% |
| Sep 30, 2025 | 22.12% |
| Jun 30, 2025 | 173.55% |
| Mar 31, 2025 | 150.64% |
| Dec 31, 2024 | 48.21% |
| Sep 30, 2024 | 161.51% |
| Jun 30, 2024 | -23.50% |
| Mar 31, 2024 | -18.38% |
| Dec 31, 2023 | -26.56% |
| Sep 30, 2023 | -61.93% |
| Jun 30, 2023 | -59.26% |
| Mar 31, 2023 | -58.84% |
| Dec 31, 2022 | 5.45% |
| Sep 30, 2022 | 98.94% |
| Jun 30, 2022 | 129.12% |
| Mar 31, 2022 | 137.73% |
| Dec 31, 2018 | 4.32% |
| Sep 30, 2018 | 4.37% |